Literature DB >> 21162596

Pharmacologic management of acutely agitated pediatric patients.

Loretta Sonnier1, Drew Barzman.   

Abstract

Acute agitation is a state of behavioral dyscontrol that requires intervention. Medications available in rapid delivery formats are frequently administered to treat acute agitation, either as a chemical restraint or on a voluntary basis. Prior to initiating treatment, the etiology of agitation must be evaluated. In choosing a medication, general pharmacologic principles should be followed. Medication should be selected based on the underlying cause in conjunction with weighing the risks, benefits, and side effects of medications. There are three classes of medications administered to children and adolescents to treat agitation: antihistamines, benzodiazepines, and antipsychotics. The most concerning short-term side effects of antipsychotics are their adverse neurologic effects, neuroleptic malignant syndrome, and prolonged corrected QT interval. Compared with typical antipsychotics, atypical antipsychotics have a more favorable short-term side effect profile.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21162596     DOI: 10.2165/11538550-000000000-00000

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  58 in total

1.  Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  H Gutgesell; D Atkins; R Barst; M Buck; W Franklin; R Humes; R Ringel; R Shaddy; K A Taubert
Journal:  Circulation       Date:  1999-02-23       Impact factor: 29.690

2.  Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department.

Authors:  Thomas W Lukens; Stephen J Wolf; Jonathan A Edlow; Samina Shahabuddin; Michael H Allen; Glenn W Currier; Andy S Jagoda
Journal:  Ann Emerg Med       Date:  2006-01       Impact factor: 5.721

Review 3.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.

Authors:  Christoph U Correll
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-01       Impact factor: 8.829

Review 4.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

Authors:  A H Glassman; J T Bigger
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

Review 5.  Best clinical practice with ziprasidone IM: update after 2 years of experience.

Authors:  Dan L Zimbroff; Michael H Allen; John Battaglia; Leslie Citrome; Avrim Fishkind; Andrew Francis; Daniel L Herr; Douglas Hughes; Marc Martel; Horacio Preval; Ruth Ross
Journal:  CNS Spectr       Date:  2005-09       Impact factor: 3.790

6.  "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings.

Authors:  Elizabeth Pappadopulos; Peter S Jensen; Sarah B Schur; James C MacIntyre; Scott Ketner; Kimberly Van Orden; Jeffrey Sverd; Sadhana Sardana; David Woodlock; Robert Schweitzer; David Rube
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

Review 7.  Intramuscular olanzapine: a review of its use in the management of acute agitation.

Authors:  Antona J Wagstaff; Jane Easton; Lesley J Scott
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed.

Authors:  Drew H Barzman; Melissa P DelBello; Jacob J Forrester; Paul E Keck; Stephen M Strakowski
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-08       Impact factor: 2.576

9.  The use of restraint for pediatric psychiatric patients in emergency departments.

Authors:  David H Dorfman; Beth Kastner
Journal:  Pediatr Emerg Care       Date:  2004-03       Impact factor: 1.454

10.  Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article.

Authors:  L Keith Scott; Rebecca Green; Paul J McCarthy; Steven A Conrad
Journal:  J Neurosurg Pediatr       Date:  2009-06       Impact factor: 2.375

View more
  6 in total

Review 1.  Practical suicide-risk management for the busy primary care physician.

Authors:  Anna K McDowell; Timothy W Lineberry; J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2011-06-27       Impact factor: 7.616

2.  Pharmacologic Management of Agitation and Aggression in a Pediatric Emergency Department - A Retrospective Cohort Study.

Authors:  Jennifer G Kendrick; Ran D Goldman; Roxane R Carr
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Nov-Dec

Review 3.  Child Psychiatric Emergencies: Updates on Trends, Clinical Care, and Practice Challenges.

Authors:  Beau Carubia; Amy Becker; B Harrison Levine
Journal:  Curr Psychiatry Rep       Date:  2016-04       Impact factor: 5.285

Review 4.  The pharmacologic management of delirium in children and adolescents.

Authors:  Susan Beckwitt Turkel; Alan Hanft
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

5.  Role of Benzodiazepines in the management of agitation due to inappropriate use of naltrexone.

Authors:  Ali Mohammad Sabzghabaee; Nastaran Eizadi-Mood; Farzad Gheshlaghi; Azam Javani; Shahin Shirani; Safieh Aghaabdollahian
Journal:  Iran J Nurs Midwifery Res       Date:  2012-07

6.  Best Practices for Evaluation and Treatment of Agitated Children and Adolescents (BETA) in the Emergency Department: Consensus Statement of the American Association for Emergency Psychiatry.

Authors:  Ruth Gerson; Nasuh Malas; Vera Feuer; Gabrielle H Silver; Raghuram Prasad; Megan M Mroczkowski
Journal:  West J Emerg Med       Date:  2019-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.